{"id":2448,"date":"2008-04-05T22:41:34","date_gmt":"2008-04-06T02:41:34","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=2448"},"modified":"2008-04-05T22:42:00","modified_gmt":"2008-04-06T02:42:00","slug":"farmacologia-riesgo-de-reacciones-cutaneas-graves-y-hepatitis-fulminante-con-el-uso-de-moxifloxacino-avelox","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/2448","title":{"rendered":"Riesgo de Reacciones Cut\u00e1neas Graves y Hepatitis fulminante con el uso de Moxifloxacino (Avelox)"},"content":{"rendered":"<p>Estimados Colegas, les env\u00edo la nota informativa emitida el 21 de Febrero de 2008, por la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AGEMED), sobre riesgo de Reacciones Cut\u00e1neas Graves y Hepatitis fulminante con el uso de Moxifloxacino (Avelox).<\/p>\n<p><!--more--><\/p>\n<p><a href=\"http:\/\/piel-l.org\/blog\/wp-content\/uploads\/2008\/03\/193\/moxifloxacino.pdf\" title=\"moxifloxacino.pdf\">moxifloxacino.pdf<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Estimados Colegas, les env\u00edo la nota informativa emitida el 21 de Febrero de 2008, por la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AGEMED), sobre riesgo de Reacciones Cut\u00e1neas Graves y Hepatitis fulminante con el uso de Moxifloxacino (Avelox).<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-2448","post","type-post","status-publish","format-standard","","category-farmacologia"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/2448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=2448"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/2448\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=2448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=2448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=2448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}